HIIFS
MACK

Harel Insurance Investments & Financial Services’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-8
Closed -$3K – 448
2017
Q2 		$3K Buy
+8
New +$163 ﹤0.01% 416

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Harel Insurance Investments & Financial Services's MACK Position: Q3 2017 in Review

Harel Insurance Investments & Financial Services sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 8 shares — an estimated $3K sold.

Harel Insurance Investments & Financial Services first reported a position in MACK in Q2 2017 and held it in 1 quarter. The position peaked at $3K in Q2 2017. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

  • Harel Insurance Investments & Financial Services reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 8 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $3K.
  • Harel Insurance Investments & Financial Services first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
  • Harel Insurance Investments & Financial Services's Merrimack Pharmaceuticals, Inc. position peaked at $3K in Q2 2017.
  • 73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q3 2017, filed 2 Nov 2017.